Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy
A phase 2/3 trial of Izalontamab brengitecan, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
Overview
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) is a phase 2/3 interventional study registered as NCT07100080 by Bristol-Myers Squibb, with 500 participants planned, started 2025-11-05 and due to reach its primary completion in 2028-12-15. Interventions recorded: Iza-bren, Carboplatin, Cisplatin, Pemetrexed. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU
Shares Izalontamab brengitecan, Pemetrexed, Cisplatin, Carboplatin.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialA Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialA Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin.
- TrialFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialStudy of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.